Analyst Comment

Dagens aktienyheder 05/01-2026: Gubra

Gubra har her til morgen annonceret, at det bliver Dr. Thomas Langenickel som overtager rollen Chief Medical and Development Officer. Dr. Langenickel bringer mere end to årtiers erfaring fra big pharma og biotech med sig og har senest været CMO hos Ethris, samt har haft ledende stillinger hos Novartis som Executive Director of Translational Medicine and Profiling samt hos Bristol Myers Squibb som Medical Director. En udnævnelse, der nok skal ses i lyset af skifte i fokus, hvor selskabet rykker sig mere mod at bringe produkter længere frem før de partnere tages ind, en strategi man allerede ser med UCN2-programmet. Læs hele nyheden her. https://www.inderes.dk/releases/gubra-appoints-dr-thomas-langenickel-as-chief-medical-and-development-officer

Disclaimer: HC Andersen Capital modtager betaling fra de nævnte selskaber for en digital IR abonnementsaftale. /Jesper Thomsen d. 05/01-2026 kl. 08.48.

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.